Kevin Conroy: I’m thrilled to announce the launch of Oncodetect by Exact Sciences
Kevin Conroy, Chairman and CEO at Exact Sciences, shared a post on LinkedIn:
“At Exact Sciences, we’re transforming cancer care through screening, treatment guidance, and monitoring. We aim to give patients and their doctors clearer answers when they matter most.
Today, I’m thrilled to announce the launch of Oncodetect, our molecular residual disease (MRD) test. Oncodetect helps empower patients and clinicians with insights to answer: Did my cancer respond to therapy? Do I still have cancer? Do I have evidence of cancer recurrence?
The Oncodetect test is the second of three new tests launching this year, an extraordinary milestone. Congratulations to the entire Exact Sciences team on this achievement. Your relentless dedication brought this test to patients and with it, another step forward in our purpose to help eradicate cancer.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023